Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

Medical Oncology

Volumn 24, Issue 3, 2007, Pages 318-322

  Birgegård, Gunnar ^a   Dahl, Fredrik ^b   Glimelius, Bengt ^a,c   Landegren, Ulf ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Beta globin mRNA; Epoetin treatment; Molecular markers; Response marker; Response prediction

Indexed keywords

BETA GLOBIN; HEMOGLOBIN; MOLECULAR MARKER; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG RESPONSE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; SENSITIVITY AND SPECIFICITY;

ANEMIA; BETA-GLOBULINS; BIOLOGICAL MARKERS; CELL COUNT; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; NEOPLASMS; RETICULOCYTES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 36248972555     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0008-x     Document Type: Article

References (15)

1. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84(Suppl 1):31-7
2. Pohl GM, Ludwig H. Supportive treatment for anemic cancer patients. Wien Med Wochenschr 2004;154:226-34
3. Littlewood TJ. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Front Radiat Ther Oncol 2002;37:34-7
4. Osterborg A, Brandberg Y. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2003;97:3125-6; author reply 3126-7
5. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 1997;34:20-6
6. Ludwig H. Epoetin beta in oncology: examining the current evidence. Future Oncol 2006;2:21-38
7. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
8. Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993;82:2010-6
9. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-53
10. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. Asaio J 2001;47:82-5
11. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94
12. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46
13. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996;81:434-41
14. Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 1998;15(Suppl 1):S38-46
15. Hagberg A, Barbany G, Landegren U, Birgegard G. Beta-globin mRNA increases rapidly during erythropoietin treatment. Scand J Clin Lab Invest 2003;63:239-45